Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder Apr 1, 2019
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 Mar 28, 2019
VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 Mar 14, 2019
VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101 Mar 13, 2019
VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 Mar 7, 2019
VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia Feb 19, 2019
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10 Feb 13, 2019
